Topical ruxolitinib is promising as sole or adjunctive therapy in treating maculopapular rash of acute and chronic skin GVHD
Zahra Hudda, Amanda Flannery, Ashley Teusink‐Cross, Stella M. Davies, Pooja Khandelwal
Topics & Concepts
MedicineMaculopapular rashRuxolitinibRashDermatologyImmunologyBone marrowMyelofibrosisCutaneous lymphoproliferative disorders researchAutoimmune Bullous Skin DiseasesCAR-T cell therapy research